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a b s t r a c t
During progression of cervical cancer, human papillomavirus genomes and cellular tumor suppressor
genes can become methylated. Toward a better understanding of these biomarkers, we studied 104
samples with HPV16, 18, 31, and 45 representing ﬁve pathological categories from asymptomatic
infection to cancer. We grouped all samples by HPV type and pathology and measured the overall
methylation of informative amplicons of HPV late genes and the cellular DAPK gene. Methylation of all
four HPV types as well as of the DAPK gene is lowest in asymptomatic infection and increases
successively in all four pathological categories during progression to cancer. 27 out of 28 cancer samples
showed methylation both in the L2/L1 genes as well as in DAPK, but a much lower fraction in all other
pathological categories. We discuss the problem to develop diagnostic tests based on complex
methylation patterns that make it difﬁcult to classify amplicons as “methylated” or “unmethylated”.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Cervical cancer, premalignant cervical lesions and non-
neoplastic HPV infections, i.e. atypical cells of undetermined
signiﬁcance (ASCUS) and cervical intraepithelial neoplasia (CIN),
are diagnosed by cytology (Papanicolaou test, Pap test), colpo-
scopic inspection, and histological examination of biopsies. These
tests and procedures are successful at decreasing the incidence of
cervical cancer, but their rate of false diagnoses is a matter of
concern (Nanda et al., 2000; Stoler and Schiffman, 2001). Detec-
tion of the DNA of high-risk human papillomavirus (HPV) types
(Munoz et al., 2003; Bernard et al., 2010), the primary cause of
cervical cancer, has become a powerful criterion to amend these
procedures, and has greatly increased the sensitivity of screening
(Bulkmans et al., 2007; Mayrand et al., 2007; Naucler et al., 2007).
However, since the fraction of women being infected by HPVs at
some time of their lives (480%) vastly exceed the incidence rate
of cervical cancer (about 1%), and since a positive HPV DNA test
often indicates a transient infection rather than a developing
cervical cancer, HPV DNA diagnosis alone is not sufﬁcient to
distinguish women with benign infections from those requiring
intensive management. In order to prevent unnecessary proce-
dures on patients with abnormal Pap smears who are not at risk
for developing cervical cancer, gynecologic practice needs tests
that are sensitive and speciﬁc to detect high-risk patients. Numer-
ous attempts have been made to measure markers that change as
the result of HPV-dependent carcinogenesis, but these tests are
still of limited beneﬁt (von Knebel Doeberitz, 2002).
The molecular mechanisms involved in the progression of asymp-
tomatic or low-grade HPV infections to cervical cancer are yet poorly
understood, but include the methylation of many of those cellular
genes that are also epigenetically affected in cancers of other organ
sites and without an HPV etiology. The search of clinically useful
epigenetic biomarkers of cervical cancer that may allow risk stratiﬁ-
cation in patients began relatively recently, but this ﬁeld of research
expanded rapidly, and a review (Wentzensen et al., 2009) compared
studies of more than 60 cellular genes. Unfortunately, this meta-
analysis came to the conclusion that there is currently no single
methylation marker that that has the appropriate performance to
serve as cervical cancer biomarker. The reviewed studies point only to
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few genes, notably DAPK (death associated protein kinase 1) and
RARB (retinoic acid receptor beta), which might be attractive targets
of further evaluations. Notably, these two markers stood out in a large
epidemiological study comparing a panel of twenty cellular methyla-
tion targets (Feng et al., 2005).
Independently of these studies of cellular genes, our group has
investigated how methylation affects HPV genomes in different
stages of cervical neoplastic disease (Kalantari et al., 2004, 2008a,
2010; Badal et al., 2004; Turan et al., 2006, 2007), and our ﬁndings
have been conﬁrmed and expanded by others (Brandsma et al.,
2009; Fernandez et al., 2009; Sun et al., 2011; Clarke et al., 2012;
Mirabello et al., 2012a). A recent review summarizes this ﬁeld
(Johannsen and Lambert, 2013). Methylation of HPV16 and 18
increases among viral infections progressing from asymptomatic
infection through low-grade and high-grade disease and malig-
nancy. This effect is particularly pronounced in the late genes L2
and L1, whose products are not required for neoplastic processes.
Methylation may affect the whole viral genome, however,
although methylation is a repression mechanism (Bird, 2002). This
is possible since neoplastic cells normally contain numerous HPV
genomes. As long as one single HPV genome is spared from
methylation, it maintains the carcinogenic process, although the
other HPV genomes in the same cell may be transcriptionally
silenced by methylation (Van Tine et al., 2004). The exact trigger of
HPV methylation is not well understood, but there is evidence that
methylation correlates with recombination between the HPV gen-
ome and chromosomal DNA (Kalantari et al., 2008a, 2008b, 2010).
Studies not related to methylation have shown that HPV genomes
frequently integrate into the cellular DNA in cancer, but it is disputed
whether this mechanism is only a frequent event or mechanistically
necessary (Daniel et al., 1997; Ueda et al., 2003; Hudelist et al., 2004;
Arias-Pulido et al., 2006; Kulmala et al., 2006; Briolat et al., 2007; Pett
and Coleman, 2007; Häfner et al., 2008; Vinokurova et al., 2008;
Campitelli et al., 2012; Xu et al., 2013). Foreign DNA that integrates
into mammalian chromosomal DNA is known to be a preferred
methylation target, and therefore a correlation between HPV recom-
bination and HPV DNA methylation may have nothing to do with the
properties of the HPV genome and the biology of the virus (Doerﬂer
et al., 2001). There is evidence that integration of HPV genomes
favors the carcinogenic process as it leads to increased E6 and E7
oncoproteins transcription by interference with negative feedback by
E2 proteins (Tan et al., 1994); transcriptional induction by the nuclear
matrix (Stünkel et al., 2000), and stabilized E6/E7 transcripts (Jeon
et al., 1995; Häfner et al., 2008).
The study reported here had the primary goal to compare the
methylation of HPV late genes with methylation of the DAPK
promoter, and with histological or cytological diagnoses among
high-risk patients that were referred to a colposcopy clinic based
on abnormal cervical cytology. Based on the literature cited above,
we considered DAPK the most promising among the cellular
epigenetic markers and we intended to compare this diagnosis
with that of the viral late gene methylation. Aside from HPV16 and
HPV18, our study targeted HPV31 and HPV45, which had not yet
been studied when this research was done, but has been reported
since then (Wentzensen et al., 2012). Our research targeted the
promoter region of the DAPK gene, and two or three amplicons of
the L2 and L1 genes of the four high-risk HPV types.
Results
Sample identiﬁcation, clinical diagnosis and evaluation
of DNA methylation
The objective of this study was to establish the methylation of
CpG dinucleotides in two or three segments of the L2 and L1 genes
of HPV16, 18, 31, and 45, and compare it with the CpG methylation
of the promoter of the cellular DAPK gene in order to analyze the
viral and cellular epigenetic changes as potentially useful clinical
progression markers of cervical cancer.
All samples of precursor lesions of cervical cancers and of
asymptomatic HPV infection were selected based on the HPV
typing of the DNA of consecutive patients of a colposcopy clinic
of the University of California Irvine as described in the Materials
and methods section. This cohort yielded 50 samples with HPV16,
nine with HPV18, eleven with HPV31, and six with HPV45. As this
cohort did not contain patients with invasive cancers, we com-
plemented these samples with material from a Norwegian cervical
cancer archive, namely 11 samples with HPV16, four samples with
HPV18, four samples with HPV31, and six samples with HPV45. We
also included the analysis of C33A and SiHa cells with HPV16, and
HeLa cells with HPV18, and report these three cell lines as cancers.
Most Californian patients were diagnosed prior to colposcopy
by cytology and if medically indicated as part of the colposcopic
examination by histology. Many of these diagnoses conﬁrmed one
another, e.g. patients with a low-grade squamous intraepithelial
lesion (LSIL) by cytology were often found to have a cervical
intraepithelial neoplasia grade I (CIN1) by histology. We sorted our
samples according to these cytologic and histologic diagnoses,
using in cases of discrepancy the higher grading of a lesion, i.e. a
patient with LSIL and CIN3 is included in the category HSIL/CIN2-3.
Our molecular data were based on analysis of cytological samples
with the exception of cancer biopsies.
Methylation data were established for two or three, respec-
tively, amplicons of the L2 and L1 genes of each HPV types, which
had been found by us and others to be among the most highly
methylated parts of the HPV genomes (Kalantari et al., 2004;
Turan et al., 2006; Brandsma et al., 2009; Sun et al., 2011;
Wentzensen et al., 2012), as well as for the promoter sequences
of DAPK. Samples may contain cell and viral populations with
diverse epigenetic states and histories. Many CpG residues in any
particular genomic position can be completely methylated or
unmethylated. Alternatively, a sample may contain molecules with
mixtures of methylated and unmethylated CpGs in the same
position (a sequencing output of overlapping C and T peaks). We
report samples with mixtures of methylated and unmethylated
CpGs as “methylated”, as they clearly contained HPV or DAPK
populations with methylated CpGs.
Previous studies from our lab and others have shown that
sporadic and low levels of CpG methylation occur in most HPV16
samples, including those derived from asymptomatic infection,
low-grade lesions, and cell cultures with episomal HPV16 gen-
omes. At this point no criterion exists to assign CpGs in any
speciﬁc genomic position a diagnostically superior status, nor is it
possible to deﬁne unequivocally a certain percentage of methyla-
tion as a diagnostically relevant threshold, making it difﬁcult to
classify individual samples as unambiguously “methylated” or
“unmethylated”. As the principal output of our study, we therefore
measured and reported the total number and percentage of
methylated CpGs in all molecules that fall into any speciﬁc
pathological category. All details of the methylation patterns of
all amplicons are reported graphically, and we present statistical
analyses as ﬁrst steps to deﬁne quantitative criteria for the use of
methylation data.
Methylation of the L2/L1 amplicons and the cellular DAPK promoter
in samples containing HPV16
Sixty-three samples contained HPV16, and the methylation of
their L2/L1 and DAPK methylation is shown in Fig. 1 and quantita-
tively summarized in Table 1. In HPV16, only 10–12.2% of all CpGs
are methylated in asymptomatic infection and ASCUS (atypical
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squamous cells of undetermined signiﬁcance). This fraction
slightly increases in LSIL/CIN1 samples to 13.6%, in HSIL/CIN2-3
lesions to 31.9%, and in cancer to 83.1%. At the DAPK promoter,
9.7–12.5% of all CpGs are methylated in asymptomatic infection
and ASCUS, and there is an increase in LSIL/CIN1 to 23.2%, in HSIL/
CIN2-3 lesions to 27.4%, and in cancer to 54.8%. HPV16 methylation
is in precancerous lesions higher in the L2/L1 segment (position
5602–5726) than in the 3′–L1 segment (position 7091–7270),
which was the primary target of our previous published studies,
and is clearly a superior target for future analyses. This is a novel
observation, which suggests to address in the future studies
preferentially the L2/L1 segment.
In spite of the limits of classifying individual amplicons
unambiguously as methylated or unmethylated, we note that all
13 cancers showed some methylation in L2/L1 as well as in DAPK,
while only 14 and 11 out of 21 HSIL/CIN2-3 samples, respectively,
showed methylation both in HPV16 and DAPK. The reverse can
also be observed, as there were six HSIL/CIN2-3 samples that
completely lacked methylation both in the HPV16 and DAPK, and
one may speculate that these may be samples with a low
propensity to progress. The mean percent methylation in L2/L1
samples increased signiﬁcantly with disease grade from 8% for
asymptomatic samples to 83% for invasive cancer (po0.001). For
DAPK, percent methylation increased signiﬁcantly from a mean of
13–59% (p¼0.004).
Methylation of the L2/L1 amplicons and the cellular DAPK promoter
in samples containing HPV18
Among 14 samples with HPV18 (Fig. 2), none of the two
asymptomatic infections showed methylation in the HPV ampli-
cons, while there were ﬁve out of 42 CpGs (11.9%) methylated in
three samples with ASCUS, seven out of 28 CpGs (25%) in two
samples with LSIL/CIN1, 21 out of 28 CpGs (75%) in two HSIL/CIN2-
3 lesions, and to 56 out of 70 CpGs (80%) in cancer. For DAPK, the
corresponding percentages were 6.3%, 0%, 18.8%, 18.8%, and 77.5%
in the ﬁve pathological groups. All ﬁve HPV18 cancers showed
some methylation both in L2/L1 and in DAPK, but only two out of
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Fig. 1. Methylation of the 5′ PCR amplicons of the HPV-16 L2 and L1 genes and the DAPK promoter in exfoliated cells of patients with abnormal Pap smears: direct
sequencing of bisulﬁte treated and PCR ampliﬁed DNA. Each row identiﬁes a patient in the corresponding pathological category, and each column a CpG dinucleotide in the
respective genomic position of HPV16 and the DAPK gene. Black rectangles indicate methylation, white rectangles lack of methylation.
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nine samples in the other four pathological categories shared this
property. Percent methylation in samples increased signiﬁcantly
with grade for L1/L2 (po0.001) and for DAPK (p¼0.004).
Methylation of the L2/L1 amplicons and the cellular DAPK promoter
in samples containing HPV31
Among 15 samples with HPV31 (Fig. 3), there was no L2/L1
methylation in the only asymptomatic infection, three out of 54
CpGs (5.6%) were methylated in three samples with ASCUS, eleven
out of 54 CpGs (20.4%) in three samples with LSIL/CIN1, 39 out of
72 CpGs (54.2%) in four HSIL/CIN2-3 lesions, and 35 out of 72 CpGs
(48.6%) in four cancers. For DAPK, the corresponding percentages
were 0%, 4.2%, 16.7%, 9.4%, and 62.5% in the ﬁve pathological
groups. Three out of four cancer samples showed some methyla-
tion both in L2/L1 and DAPK, and ﬁve out of nine samples in the
other four pathological categories. Percent methylation in samples
increased signiﬁcantly with grade for L1/L2 (po0.008). For DAPK,
the increase in percent methylation with grade form 0% to 63% was
not statistically signiﬁcant (p¼0.064).
Methylation of the L2/L1 amplicons and the cellular DAPK promoter
in samples containing HPV45
There were twelve samples with HPV45 (Fig. 4). The only
asymptomatic infection was unmethylated in L2/L1. There was
Table 1
Methylation of CpGs of HPV16, 18, 31 and 45 and DAPK amplicons and statistical evaluations.
Methylated CpGs in L2/L1 Percent of methylated CpG
in L2/L1 per sample
Methylated CpGs in DAPK Percent of methylated
CpGs in DAPK per sample
HPV16 (63 samples) N/total Mean (SE) N/total Mean (SE)
Asymptomatic 5/50 (10.0%) 8.3 (9.2) 6/48 (12.5%) 12.5 (12.7)
ASCUS 11/90 (12.2%) 12.2 (7.6) 7/72 (9.7%) 9.7 (10.4)
LSIL/CIN1 19/140(13.6%) 13.6 (6.1) 26/112 (23.2%) 23.2 (8.3)
HSIL/CIN2-3 67/210 (31.9%) 31.9 (4.9) 46/168 (27.4%) 27.4 (6.8)
Invasive cancer 108/130 (83.1%) 83.1 (6.3) 57/104 (54.8%) 58.7 (8.6)
p-value po0.0005a po0.0005b po0.0005a p¼0.004b
HPV18 (14 samples)
Asymptomatic 0/28 (0.0%) 0.0 (8.1) 1/16 (6.3%) 6.3 (15.1)
ASCUS 5/42 (11.9%) 11.9 (6.6) 0/56 (0.0%) 0.0 (12.3)
LSIL/CIN1 7/28 (25.0%) 25.0 (8.1) 3/16 (18.8%) 18.8 (15.1)
HSIL/CIN2-3 21/28 (75.0%) 75.0 (8.1) 3/16 (18.8%) 18.8 (15.1)
Invasive cancer 56/70 (80.0%) 81.4 (5.1) 31/40 (77.5%) 77.5 (9.6)
p-value po0.0005a po0.0005b po0.0005a p¼0.004b
HPV31 (15 samples)
Asymptomatic 0/18 (0.0%) 0.0 (16.1) 0/8 (0.0%) 0.0 (26.2)
ASCUS 3/54 (5.6%) 5.6 (9.3) 1/24 (4.2%) 4.2 (15.2)
LSIL/CIN1 11/54 (20.4%) 20.4 (9.3) 4/24 (16.7%) 16.7 (15.2)
HSIL/CIN2-3 39/72 (54.2%) 54.2 (8.1) 3/32 (9.4%) 9.4 (13.1)
Invasive cancer 35/72 (48.6%) 48.6 (8.1) 20/32 (62.5%) 62.5 (13.1)
p-value po0.0005a p¼0.008b po0.0005a p¼0.064b
HPV45 (12 samples)
Asymptomatic 0/18 (0.0%) 0.0 (15.6) 0/8 (0.0%) 0.0 (28.0)
ASCUS N/A N/A N/A N/A
LSIL/CIN1 0/18 (0.0%) 0.0 (15.6) 1/8 (12.5%) 12.5 (28.0)
HSIL/CIN2-3 59/72 (81.9%) 81.9 (7.8) 5/32 (15.6%) 15.6 (14.0)
Invasive cancer 102/108 (94.4%) 94.4 (6.4) 38/48 (79.2%) 79.2 (11.4)
p-value po0.0005a p¼0.001b po0.0005a p¼0.021b
SE: standard error.
a Chi-square test for trend.
b F-test.
Fig. 2. Methylation of the 5′ PCR amplicons of the HPV-18 L2 and L1 genes and the DAPK promoter in exfoliated cells of patients with abnormal Pap smears: direct
sequencing of bisulﬁte treated and PCR ampliﬁed DNA.
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no sample with ASCUS. The only sample with LSIL/CIN1 had no
methylation in the HPV45 amplicons. Four HSIL/CIN2-3 samples
had 59 out of 72 CpGs (81.9%) methylated, and six cancer samples
102/108 CpGs (94.4%). For DAPK, the corresponding percentages
were 0%, 12.5%, 15.6%, and 79.2% in the four pathological groups
that contained at least one sample. (po0.001 for trend). All six
cancer samples showed some methylation both in L2/L1 and
DAPK, but only two of the six samples in the other four patholo-
gical categories.
Separate consideration of DAPK methylation
In order to better evaluate the DAPK marker, we added the data
for DAPK for infections of all four HPV types. For DAPK, methyla-
tion of all CpGs was 10% (asymptomatic infection), 5.3% (ASCUS),
17.5% (low-grade lesions), 23.2% (high-grade lesions), and 63.5%
(cancer).
Sensitivity and speciﬁcity
Our research is based on the hypothesis that strongly methy-
lated samples identify molecular changes driving these lesions
toward invasive cancer, irrespective of the cytological diagnosis.
With the caveat of this hypothetical and molecular deﬁnition, 50%
methylation for L1/L2 samples for all HPV types as a cutoff for
detection of invasive cancer has good sensitivity at 89% and
speciﬁcity at 84%. Sensitivity and speciﬁcity remain high (both
80–90%) for cutoffs between 50% and 69% methylation (Fig. 5A).
When using DAPK methylation to discriminate invasive cancer
from lesser grade disease, sensitivity is 89% when 25% methylation
is used as a critical cutoff for cancer detection, speciﬁcity is lower
at 76% (Fig. 5B). When the critical cutoff is increased to 38%,
speciﬁcity increases to 88% with a loss of sensitivity (75%).
Sensitivity and speciﬁcity for detection of HSIL/cancer vs. lesser
grade disease in L1/L2 samples are 80% and 89% respectively for
methylation Z30%. Sensitivity for detection of HSIL/cancer in
DAPK samples, however, is notably lower at 59% with speciﬁcity¼
82% for methylation Z24%.
Discussion
Our discovery of HPV16 and 18 methylation and their change
during cervical carcinogenesis (Kalantari et al., 2004; Badal et al.,
2004; Turan et al., 2006) have become generally conﬁrmed and led
to a major expansion of the available data base (Brandsma et al.,
2009; Fernandez et al., 2009; Sun et al., 2011; Clarke et al., 2012;
Mirabello et al., 2012a; Lorincz et al., 2013) and extension of this
phenomenon to HPV31 and 45 (Wentzensen et al., 2012). It is now
generally accepted that methylation is increased in high-grade
lesions and cancer compared to asymptomatic infection or low-
grade lesions, and that this mechanisms targets the late genes
more than the early genes or the long control region. The question
of the underlying mechanism has not become revisited after our
reports of correlation between methylation and recombination
between HPV genomes and cellular DNA (Kalantari et al., 2008a,
2008b, 2010), suggesting that transcriptionally inactive parts of
the genome may become part of the heterochromatin like most
exogenous DNAwithout relevance of the identity of the HPV genes
(Doerﬂer et al., 2001). In contrast, endogenous tumor suppressor
genes may be targeted at random by cellular de novo methylation,
and cells with tumor suppressor genes inactivated by methylation
may expand in number due the phenotypic consequences of the
gene inactivation. While HPV methylation and cellular gene
methylation are likely enzymatically related, the underlying
mechanistic logic is clearly different.
Our research adds new aspects to the epigenetic proﬁling of
HPV lesions by concomitantly analyzing the methylation of the
late genes of four high-risk HPV-types HPV16, 18, 31, and 45
and that of a cellular gene, DAPK, one of the best cellular
biomarkers for the progression of cervical cancer. It is also unique
by including a substantial number of cervical cancers beyond the
Fig. 3. Methylation of the 5′ PCR amplicons of the HPV-31 L2 and L1 genes and the DAPK promoter in exfoliated cells of patients with abnormal Pap smears: direct
sequencing of bisulﬁte treated and PCR ampliﬁed DNA.
Fig. 4. Methylation of the 5′ PCR amplicons of the HPV-45 L2 and L1 gene2 and the DAPK promoter in exfoliated cells of patients with abnormal Pap smears: direct
sequencing of bisulﬁte treated and PCR ampliﬁed DNA.
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study of high-grade precursor lesions. Our study conﬁrms that
methylation of L2/L1 occurs in all four HPV types, and increases
between all ﬁve pathological categories, asymptomatic infection,
ASCUS, LSIL/CIN1, HSIL/CIN2-3 and cervical cancer, the biggest
increases occurring in the two progression steps between LSIL/
CIN1 and cancer. Interestingly, a similar gain of methylation occurs
in the methylation of DAPK, in contrast to the data from others
(Sun et al., 2011).
Our investigation is a pilot study of the potential of these
biomarkers, as the numbers of samples, especially for HPV18, 31,
and 45, is low. The value of biomarkers that are fully developed in
invasive cancer and much less prevalent in patients with low-
grade and high-grade lesion is at this point still debatable. It is our
hypothesis that highly methylated LSIL/CIN1 and HSIL/CIN2-3
samples are those that have molecularly undergone changes that
predestine them to develop into cancers. But the answer to the
question of whether “high methylation” in general and which level
of methylation in details identiﬁes cells with an irrevocable
propensity to grow into invasive cancer can only be resolved by
future studies, in spite of support by other labs for the predictive
value of HPV16 methylation (Mirabello et al., 2012b; Lorincz et al.,
2013). The hypothesis needs further epidemiological and molecu-
lar evaluation. Epidemiological research could take the form of
retrospective longitudinal studies, and ask whether cancer
patients showed higher HPV L2/L1 and DAPK methylation in
archival precancerous samples. Molecular research could reveal
that the methylation is a mechanistic part of the etiological
process. For example, as the normal life cycle of HPVs is irrevoc-
ably terminated by chromosomal recombination, methylation of
the L2/L1 genes ensuing from recombination likely correlates with
an interruption of E2 gene transcription and increased E6/E7
oncogene expression. On the other side, methylation of cellular
tumor suppressor genes such as DAPK may suppress functions
relevant for the maintenance of the non-cancerous state. We
suggest that subsequent to such epidemiological and molecular
conﬁrmations the combination methylation analyses of HPV L2/L1
and cellular genes like DAPK and technical improvements by next-
generation-sequencing will lead to clinically useful tests of early
detection of cervical cancer progression.
Materials and methods
Clinical specimens and diagnoses
From October 2009 to May 2010 552 consecutive patients were
enrolled who attended the University of California, Irvine Family
Health Center Colposcopy Clinic in Santa Ana, California. Patients
attending this clinic were considered to be a high-risk population
as evidenced by abnormal referral cervical cytology. After securing
patient's written informed consent, an additional Pap smear was
obtained during the colposcopic examination and analyzed during
our research. Cervical biopsies were obtained when indicated
clinically but were not studied molecularly. Our study noted the
cytological as well as histological (if applicable) diagnoses of all
patients, but, if divergent, reports only the higher progression
state (Figs. 1–4). The patients were triaged for their cytological
and/or histological diagnoses as outlined in algorithms set forth by
the American Society of Colposcopy and Cervical Pathology
(ASCCP). All clinical evaluations were overseen by the Gynecologic
Oncology Research Fellow (D.M.C.) and Attending Gynecologic
Oncologist (K.S.T.). The molecular biologists (M.K., I.E.C.M., S.K., B.
Y., and H.U.B.) were blinded to clinical information except to the
enrollment criterion. The molecular data did not alter the clinical
management of the patients. Exfoliated cells taken were taken
from these patients by cotton brush, suspended in PreserveCyt
solution, and DNA was prepared with the QIAamp DNA mini kit
(Qiagen) according to the manufacturer's recommendations. This
research had been approved by the Institutional Review Board of
the University of California Irvine.
As this cohort did not contain any cancer patients, this
sampling did not create a foundation for our objective to compare
cervical cancer precursor lesions with cervical cancers. Therefore,
we added to our study 26 cervical carcinomas from a collection of
archival samples received from the Norwegian Cancer Registry,
Oslo, by Dr. Bjoern Hagmar (Kalantari et al., 2004), as well as three
widely used cervical cancer cell lines, SiHa, C33A and HeLa.
Typing of HPVs in DNA preparations from exfoliated cells
In order to identify samples with HPV16, 18, 31, and 45, all DNA
preparation were ampliﬁed with degenerated primer pair MY09/
11 targeting the L1 gene, followed by direct sequencing of the
ampliﬁcation products.
Bisulﬁte modiﬁcation
DNA sequencing subsequent to bisulﬁte modiﬁcation and PCR
ampliﬁcation (with or without additional cloning into Escherichia
coli) is a sensitive technique to measure methylcytosines
(Frommer et al., 1992). For bisulﬁte treatment, 50–1000 ng of
sample DNA supplemented with 1 mg of salmon sperm DNA in
18 ml water were denatured with 2 ml 3 M NaOH and incubated at
37 1C. After denaturation, 278 ml 4.8 M sodium bisulﬁte and 2 ml
100 mM hydroquinone were added with the mixture being incu-
bated in a thermal cycler for 20 cycles of 55 1C for 15 min and
Fig. 5. Sensitivity and speciﬁcity of percent methylation for detection of cancer. (A)
ROC curve for percentage of virus CpG methylation for detection of cells that
according to our hypothesis have progressed to a cancerous state. (B) ROC curve for
percentage of DAPK methylation for detection of cells that according to our
hypothesis have progressed to a cancerous state.
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95 1C for 30 s. The modiﬁed DNA was desalted with the QIAquick
PCR puriﬁcation protocol and desulfonated thereafter by adding
5.5 ml 3 M NaOH and 5 mg glycogen prior to 15 min incubation at
37 1C. The DNA was precipitated with 5.6 ml of 3 M sodium acetate
and 150 ml 100% ethanol and centrifuged. The pellet was washed
with 70% ethanol and dissolved in 50 ml TE buffer (10 mM Tris–
HCl; pH 8; and 1 mM EDTA).
Polymerase chain reactions, primers, and DNA sequencing of bisulﬁte
treated DNA
Our previous studies have demonstrated that cervical smears
contain mixtures of HPV genomes with diverse methylation
patterns as well as unmethylated together with methylated DNA.
This is to be expected since the collection of exfoliated cervical
cells will sample HPV infected and uninfected epithelium as well
as subsets of a lesion with different stages of disease. For the same
reason, one should also expect a mixture of methylated and
unmethylated CpGs at the promoter of DAPK. As the samples are
processed by direct sequencing of the bisulﬁte treated and PCR
ampliﬁed DNA (as opposed to cloning the reaction product and
sequencing many independent clones), methylation signals (i.e.
CpGs in bisulﬁte treated DNA) will often be overlaid by sequences
indicating unmethylated CpGs (i.e. TpGs in bisulﬁte treated DNA).
In our results, we scored all CpGs as well as jointly occurring CpG
and TpG signals in bisulﬁte treated and PCR ampliﬁed DNA as
representing methylated CpGs in the untreated DNA preparation.
Table 2 summarizes all primers that were used to amplify
bisulﬁte treated sample DNA. As representative of the methylation
of the late genes of HPV16, we targeted a segment spanning the 3′
end of L2 and the 5′ part of the L1 gene between the positions
spanning six CpG dinucleotides at the genomic positions 5602,
5608, 5611, 5617, 5709, and 5726 of HPV16. We also analyzed the
methylation status of CpGs at the positions 7091, 7136, 7145, and
7270, which had been the preferred target in all our previous
studies. The two primer pairs for HPV18 spanned CpGs at the
positions 6142, 6144, 6161, 6363, and 6366, as well as 7011, 7038,
7041, 7062, 7068, 7090, 7110, 7116, and 7122.
Three primer pairs for the analysis of HPV31 spanned CpGs at
the positions 5518, 5521, 5524, 5530, 5564, 5572, 5622, 5639 (ﬁrst
primer pair), 5843, 5879, 5881, and 5962 (second primer pair), and
6950, 6983, 7007, 7046 and 7170 (third primer pair). And two
primer pairs for the analysis of HPV45 spanned CpGs at the
positions 4795, 4855, 4890, 4893, 4899, 4908, 4938, and 4975,
as well as 6990, 7015, 7042, 7045, 7066, 7072, 7088, 7123, 7129
and 7135.
The DAPK promoter was ampliﬁed with the primer pairs shown
in Table 2 and included CpGs at position 85, 87, 98, 106, 111, 127,
130, and 147 (Narayan et al., 2003).
PCR was carried out in a 25 ml volume containing 0.2 mM of
each of the four dNTPs, 10 pmol of each primer, 2 mM MgCl2
and 1 unit of AmpliTaqGold (Applied Biosystems, Foster City,
California, USA). The PCR conditions were 94 1C for 1 min, followed
by 40 cycles of 94 1C for 10 s, 54 1C for 30 s and 68 1C for 1 min
with a ﬁnal extension at 68 1C for 7 min. The presence of PCR
products was veriﬁed by agarose gel electrophoresis. Conﬁrmed
amplicons were directly sequenced by Big Dye terminator v3.1
Cycle Sequencing with the same primers used for ampliﬁcation
(Applied Biosystems, Foster City, California, USA).
Statistical methods
The degree of methylation across grades of disease was
compared using a chi-square test for trend for testing difference
in the percent of all CpGs that were methylated and an F-test for
comparing mean percent methylation per sample by grade. Com-
bining all HPV types, sensitivity and speciﬁcity were calculated for
detection of invasive cancer at different cutoffs for percent
methylation, and ROC curves were constructed.
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